Ake Hjalmarson Gordon Tomaselli REFERENCE: Late Breaking Clinical Trials, Session 2, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida N Engl J Med 2007;357 AKE HJAL
Ake Hjalmarson
Gordon Tomaselli
REFERENCE: Late Breaking Clinical Trials, Session 2, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, FloridaN Engl J Med 2007;357AKE HJALMARSON, Sahlgrenska University, GöteborgCOMMENT: GORDON TOMASELLI, Johns Hopkins University, BaltimoreThe lipid lowering agent rosuvastatin did not bring a significant benefit to older patients with systolic heart failure, according to the findings of the CORONA study released at the American Heart Association sessions in Orlando.Ake Hjalmarsontalked with Peter Goodwin about the implications this has for using statins in older patients with heart failure.
Tags
Related Episodes
LDL-How Low?
Terje Pedersen Terje Pedersen, Ulleval University, Oslo Eugene Braunwald, Harvard University, Boston Lowering LDL Cholesterol intensively as a means of treating aortic stenosis was found to have no be
Audio Journal of Oncology Volume 16 Number 11
Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan) Sarah Maxwell and Peter Goodwin report from: American Society of Clinical Oncology
Blind For Blindness: Preventing Childhood Blindness
Hessom Razavi, Puneet Sayal, Claire Gilbert Hessom Razavi, Puneet Sayal, Claire Gilbert, London School of Hygiene and Tropical Medicine Eye doctor Hessom Razavi volunteered to go about his usual studi